Aim: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome.
Patients & methods: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10(-4) (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE.
Results: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171-0.0617, p = 5.37 × 10(-4)).
Conclusion: The GRS was associated with statin response, but the small effect size (˜2% of the average low-density lipoprotein cholesterol reduction) limits applicability.
Keywords: pharmacogenetics cholesterol; risk score; statin therapy.
Conflict of interest statement
This work was supported by:
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.Circ Cardiovasc Genet. 2012 Feb 1;5(1):58-65. doi: 10.1161/CIRCGENETICS.111.961847. Epub 2012 Jan 9. Circ Cardiovasc Genet. 2012. PMID: 22230323 Clinical Trial.
Seventeen years of statin pharmacogenetics: a systematic review.Pharmacogenomics. 2016;17(2):163-80. doi: 10.2217/pgs.15.158. Epub 2015 Dec 15. Pharmacogenomics. 2016. PMID: 26670324 Review.
A genetic risk score is significantly associated with statin therapy response in the elderly population.Clin Genet. 2017 Mar;91(3):379-385. doi: 10.1111/cge.12890. Epub 2016 Dec 12. Clin Genet. 2017. PMID: 27943270
Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.Pharmacogenet Genomics. 2013 Oct;23(10):518-25. doi: 10.1097/FPC.0b013e3283642fd6. Pharmacogenet Genomics. 2013. PMID: 23903772 Free PMC article. Clinical Trial.
Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Xenobiotica. 2011 Aug;41(8):639-51. doi: 10.3109/00498254.2011.562566. Epub 2011 Mar 22. Xenobiotica. 2011. PMID: 21425956 Review.
Cited by 3 articles
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.High Throughput. 2018 Dec 18;7(4):40. doi: 10.3390/ht7040040. High Throughput. 2018. PMID: 30567415 Free PMC article. Review.
Do Statins Have Antidepressant Effects?CNS Drugs. 2017 May;31(5):335-343. doi: 10.1007/s40263-017-0422-3. CNS Drugs. 2017. PMID: 28303466 Review.
Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment.Pharmacogenomics. 2016 Oct;17(15):1621-1628. doi: 10.2217/pgs-2016-0091. Epub 2016 Sep 20. Pharmacogenomics. 2016. PMID: 27648687 Free PMC article.
- HHSN268201100012C/HL/NHLBI NIH HHS/United States
- HHSN268201100009I/HL/NHLBI NIH HHS/United States
- N01HC95160/HL/NHLBI NIH HHS/United States
- R01 HL036310/HL/NHLBI NIH HHS/United States
- HHSN268201100010C/HL/NHLBI NIH HHS/United States
- UL1 RR025005/RR/NCRR NIH HHS/United States
- N01HC95163/HL/NHLBI NIH HHS/United States
- HHSN268201100008C/HL/NHLBI NIH HHS/United States
- HHSN268201100005G/HL/NHLBI NIH HHS/United States
- HHSN268201100008I/HL/NHLBI NIH HHS/United States
- R01 HL092577/HL/NHLBI NIH HHS/United States
- R01 HL059367/HL/NHLBI NIH HHS/United States
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- N01HC95169/HL/NHLBI NIH HHS/United States
- HHSN268201100011I/HL/NHLBI NIH HHS/United States
- HHSN268201100011C/HL/NHLBI NIH HHS/United States
- R01 HL086694/HL/NHLBI NIH HHS/United States
- R01 HL076784/HL/NHLBI NIH HHS/United States
- U01 HG004402/HG/NHGRI NIH HHS/United States
- N01HC95164/HL/NHLBI NIH HHS/United States
- N01HC95162/HL/NHLBI NIH HHS/United States
- N01HC95168/HL/NHLBI NIH HHS/United States
- R37 AG013196/AG/NIA NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- HHSN268201100005I/HL/NHLBI NIH HHS/United States
- N01HC95165/HL/NHLBI NIH HHS/United States
- N01HC95159/HL/NHLBI NIH HHS/United States
- N01HC95161/HL/NHLBI NIH HHS/United States
- N01HC95167/HL/NHLBI NIH HHS/United States
- MR/K006584/1/Medical Research Council/United Kingdom
- R01 AG013196/AG/NIA NIH HHS/United States
- HHSN268201100009C/HL/NHLBI NIH HHS/United States
- HHSN268201100005C/HL/NHLBI NIH HHS/United States
- N01HC25195/HL/NHLBI NIH HHS/United States
- R01 HL071205/HL/NHLBI NIH HHS/United States
- HHSN268201100007I/HL/NHLBI NIH HHS/United States
- N01HC95166/HL/NHLBI NIH HHS/United States
- R01 AG028321/AG/NIA NIH HHS/United States
- R01 HL087641/HL/NHLBI NIH HHS/United States
- G0600237/Medical Research Council/United Kingdom
- MC_UU_12013/5/Medical Research Council/United Kingdom
- RG/10/12/28456/British Heart Foundation/United Kingdom